A framework for evaluating markers used to select patient treatment

Area of Science:

• Biostatistics
• Clinical Trial Design
• Pharmacogenomics

Background:

• Growing interest in personalized medicine and identifying patient subgroups for targeted therapies.
• Existing methods for evaluating treatment selection markers have limitations and distinct assumptions.
• The Gail model exemplifies a risk-based approach to identifying patients for preventive treatments like tamoxifen.

Purpose of the Study:

• To develop a unified framework for evaluating treatment selection markers.
• To integrate existing approaches for marker evaluation under a common structure.
• To facilitate marker evaluation under more flexible and less restrictive assumptions.

Main Methods:

• Review and synthesis of two primary approaches to treatment selection marker evaluation.
• Development of a generalized framework encompassing both risk-based and treatment-effect-based models.
• Analysis of underlying assumptions for each existing approach.

Main Results:

• The proposed framework integrates existing methods as special cases.
• Clarification of assumptions underlying current marker evaluation techniques.
• Enabling more robust evaluation of treatment selection markers.

Conclusions:

• A comprehensive framework for treatment selection marker evaluation has been established.
• The framework allows for a unified understanding and application of different marker evaluation strategies.
• This work facilitates the identification of patients most likely to benefit from specific treatments, optimizing therapeutic outcomes.